Sofinnova Investments, Inc. Vir Biotechnology, Inc. Transaction History

Sofinnova Investments, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$6.48 - $12.48 $201,664 - $388,390	-31,121 Reduced 27.27%	83,010 $537,000
Q4 2024 Feb 14, 2025	SELL	$6.74 - $10.17 $101,875 - $153,719	-15,115 Reduced 11.69%	114,131 $837,000
Q3 2024 Nov 13, 2024	BUY	$7.26 - $10.7 $938,325 - $1.38 Million	129,246 New	129,246 $968,000
Q4 2023 Aug 15, 2024	BUY	$7.76 - $10.29 $34,881 - $46,253	4,495 New	4,495 $45,000
Q4 2023 Feb 12, 2024	SELL	$7.76 - $10.29 $3.75 Million - $4.98 Million	-483,622 Reduced 99.08%	4,495 $45,000

Q2 2023 Aug 14, 2023	SELL	$23.2 - $27.29 $3.93 Million - $4.62 Million	-169,442 Reduced 25.77%	488,117 $12 Million
Q1 2023 May 11, 2023	BUY	$22.26 - $30.85 $14.6 Million - $20.3 Million	657,559 New	657,559 $15.3 Million

243

106M

246K

126K

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $747M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.